back
SEDI Insider filing browser
| Date | Issuer | Insider | Transaction | Amount | New Balance ⓘ
The balance of securities held by registered holder at the time of the transaction. Insiders may direct multiple registered holders and hold multiple security types.
|
|
|---|---|---|---|---|---|---|
| Filed 2026-03-16 15:36 Tx date 2026-03-13 |
$XENE
Xenon Pharmaceuticals Inc. |
Mortimer, Ian Charles
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-403,584.30
-7,308 vol $55.23 each |
19,923 | |
| Filed 2026-03-16 15:35 Tx date 2026-03-12 |
$XENE
Xenon Pharmaceuticals Inc. |
Mortimer, Ian Charles
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
+12,500 vol |
27,231 | |
| Filed 2026-03-16 15:31 Tx date 2026-03-12 |
$XENE
Xenon Pharmaceuticals Inc. |
Mortimer, Ian Charles
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Share Units
57 - Exercise of rights
|
-12,500 vol |
102,500 | |
| Filed 2026-03-13 18:27 Tx date 2026-03-09 |
$XENE
Xenon Pharmaceuticals Inc. |
Mortimer, Ian Charles
5 - Senior Officer of Issuer
Direct Ownership
|
Options
51 - Exercise of options
|
-105,000 vol |
1,845,000 | |
| Filed 2026-03-13 17:32 Tx date 2026-03-09 |
$XENE
Xenon Pharmaceuticals Inc. |
Mortimer, Ian Charles
5 - Senior Officer of Issuer
Direct Ownership
|
Options
51 - Exercise of options
|
-25,000 vol |
1,950,000 | |
| Filed 2026-03-13 17:30 Tx date 2026-03-09 |
$XENE
Xenon Pharmaceuticals Inc. |
Mortimer, Ian Charles
5 - Senior Officer of Issuer
Direct Ownership
|
Options
51 - Exercise of options
|
-75,000 vol |
1,975,000 | |
| Filed 2026-03-13 17:28 Tx date 2026-03-09 |
$XENE
Xenon Pharmaceuticals Inc. |
Mortimer, Ian Charles
5 - Senior Officer of Issuer
Direct Ownership
|
Options
51 - Exercise of options
|
-25,000 vol |
||
| Filed 2026-03-13 17:27 Tx date 2026-03-09 |
$XENE
Xenon Pharmaceuticals Inc. |
Mortimer, Ian Charles
5 - Senior Officer of Issuer
Direct Ownership
|
Options
51 - Exercise of options
|
-75,000 vol |
||
| Filed 2026-03-13 17:06 Tx date 2026-03-09 |
$XENE
Xenon Pharmaceuticals Inc. |
Mortimer, Ian Charles
5 - Senior Officer of Issuer
Direct Ownership
|
Performance Share Units
57 - Exercise of rights
|
-20,000 vol |
0 | |
| Filed 2026-03-13 17:04 Tx date 2026-03-10 |
$XENE
Xenon Pharmaceuticals Inc. |
Mortimer, Ian Charles
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
$-677,357.052
-11,269 vol $60.11 each |
14,731 | |
| Filed 2026-03-13 17:02 Tx date 2026-03-09 |
$XENE
Xenon Pharmaceuticals Inc. |
Mortimer, Ian Charles
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
56 - Grant of rights
|
+20,000 vol |
26,000 | |
| Filed 2026-03-13 17:00 Tx date 2026-03-09 |
$XENE
Xenon Pharmaceuticals Inc. |
Mortimer, Ian Charles
5 - Senior Officer of Issuer
Direct Ownership
|
Performance Share Units
57 - Exercise of rights
|
+20,000 vol |
20,000 | |
| Filed 2026-03-13 16:55 Tx date 2014-11-05 |
$XENE
Xenon Pharmaceuticals Inc. |
Mortimer, Ian Charles
5 - Senior Officer of Issuer
Direct Ownership
|
Performance Share Units
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2026-03-13 16:54 Tx date 2026-03-09 |
$XENE
Xenon Pharmaceuticals Inc. |
Mortimer, Ian Charles
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-4,033,900
-65,000 vol $62.06 each |
6,000 | |
| Filed 2026-03-13 16:53 Tx date 2026-03-09 |
$XENE
Xenon Pharmaceuticals Inc. |
Mortimer, Ian Charles
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
51 - Exercise of options
|
$613,600
+65,000 vol $9.44 each |
71,000 | |
| Filed 2026-03-13 16:52 Tx date 2026-03-09 |
$XENE
Xenon Pharmaceuticals Inc. |
Mortimer, Ian Charles
5 - Senior Officer of Issuer
Direct Ownership
|
Options
51 - Exercise of options
|
-65,000 vol |
1,950,000 | |
| Filed 2026-03-13 16:47 Tx date 2026-03-09 |
$XENE
Xenon Pharmaceuticals Inc. |
Mortimer, Ian Charles
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-3,704,052.16
-61,652 vol $60.08 each |
6,000 | |
| Filed 2026-03-13 16:44 Tx date 2026-03-09 |
$XENE
Xenon Pharmaceuticals Inc. |
Mortimer, Ian Charles
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-2,568,802.48
-43,348 vol $59.26 each |
67,652 | |
| Filed 2026-03-13 16:16 Tx date 2026-03-09 |
$XENE
Xenon Pharmaceuticals Inc. |
Mortimer, Ian Charles
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
51 - Exercise of options
|
$498,750
+105,000 vol $4.75 each |
111,000 | |
| Filed 2026-03-13 16:11 Tx date 2026-03-09 |
$XENE
Xenon Pharmaceuticals Inc. |
Mortimer, Ian Charles
5 - Senior Officer of Issuer
Direct Ownership
|
Options
51 - Exercise of options
|
-25,000 vol |
2,015,000 |